Last updated: April 2, 2026
What Is LOESTRIN 21 1/20?
LOESTRIN 21 1/20 is a combined oral contraceptive (COC) tablet containing 21 active ethinyl estradiol and 1.20 mg of norethindrone acetate. It is manufactured by Allergan (acquired by AbbVie) and approved for contraception, menstrual regulation, and hormonal regulation. The drug's primary indications target women seeking reliable birth control, with a significant share in the oral contraceptive market.
Market Position and Commercial Outlook
Market Overview
The global oral contraceptives market was valued approximately at USD 7.3 billion in 2022, with a compound annual growth rate (CAGR) of 4.5% expected through 2028.[1] Key drivers include increasing awareness of reproductive health, rising female workforce participation, and expanding access in emerging markets.
Competitive Landscape
LOESTRIN 21 competes with similar monophasic pills, notably:
- Ortho Tri-Cyclen Lo (Bayer)
- Yasmin (Bayer)
- Microgynon (MSD)
- Seasonale (Allergan/Astellas)
LOESTRIN benefits from AbbVie's marketing network, established brand recognition, and favorable safety profile. It faces competition based on price points, side effect profiles, and insurance coverage.
Revenue Contribution
LOESTRIN 21 contributed approximately USD 120 million in sales worldwide in 2022.[2] While smaller than blockbuster contraceptives, it maintains steady revenue, supported by ongoing prescriptions and new patient acquisitions.
Regulatory Status and Patent Landscape
Approvals and Market Access
LOESTRIN 21 holds FDA approval since 2000 and similar approvals in Europe and other key markets. Market access depends on reimbursement policies and prescribing guidelines, which favor established brands with long-term safety data.
Patent and Exclusivity
AbbVie holds patents till 2024 protecting formulation and manufacturing processes. Patent expiry may lead to generic competition, impacting pricing and margins.
Fundamentals Analysis
| Aspect |
Details |
| Revenue (2022) |
USD 120 million (global estimate) |
| Cost of Goods Sold (COGS) |
Approx. 35% of sales, based on typical manufacturing costs |
| Gross Margin |
Estimated at 65% |
| R&D Expenses |
Approx. 10% of sales; primarily for formulation refinement and safety profile research |
| Marketing & Distribution |
15-20% of sales; driven by sales forces and advertising |
| Patent Expiration |
2024 |
Profitability and Cost Structure
LOESTRIN 21 maintains a high gross margin typical for branded generics in the contraceptive market. The accumulated patent protection supports pricing power, though the approaching expiration introduces margin compression risks with generic entries.
Investment Risks and Opportunities
Risks:
- Patent expiry in 2024 leading to generic erosion.
- Competitive pressure from new contraceptive modalities, such as long-acting reversible contraceptives (LARCs).
- Regulatory changes concerning hormonal contraceptives, particularly in regions with restrictive policies.
Opportunities:
- Expanding market share through increased awareness campaigns.
- Launching extended-formulation versions with improved efficacy or reduced side effects.
- Penetration into emerging markets with lower contraceptive adoption rates.
Conclusion
LOESTRIN 21 1/20 represents a stable revenue generator due to brand recognition and established market presence. Its near-term outlook hinges on patent exclusivity expiration, after which generic competition could heavily impact profitability. Strategic positioning and pipeline innovation are essential to sustain long-term valuation.
Key Takeaways
- The drug generated USD 120 million globally in 2022, with high gross margins.
- Patent protections expire in 2024, risking significant price erosion.
- Competition from generic versions will likely increase post-patent expiration.
- Market growth driven by changing demographics and reproductive health awareness.
- Investment decisions should weigh potential patent cliff risks against brand loyalty and market penetration strategies.
FAQs
1. How will patent expiration affect LOESTRIN 21’s market share?
Patent expiry in 2024 may lead to increased generic competition, likely reducing revenue and profitability unless the company innovates or expands into new markets.
2. Are there pending regulatory changes that could impact LOESTRIN 21?
While regulatory shifts concerning hormonal contraceptives exist, no immediate legislation targets this specific drug. Future policies on over-the-counter access or hormonal safety remain uncertain.
3. What is the potential for pipeline products related to LOESTRIN?
AbbVie’s pipeline includes extended or alternative contraceptive formulations, which could enhance long-term sales ahead of generic competition.
4. How does LOESTRIN compare to newer contraceptives like LARCs?
LARCs exhibit higher efficacy and longer durations, which may threaten oral contraceptive sales, but oral pills remain preferred for their convenience and lower upfront costs.
5. What strategic moves could extend LOESTRIN’s market viability?
Developing new formulations, expanding geographic access, and leveraging brand loyalty can mitigate patent expiry risks.
References
[1] Market Research Future. (2023). Global Contraceptive Market Analysis.
[2] Company Financial Reports, AbbVie. (2023). Annual Sales Data for LOESTRIN 21.
Note: Data is approximated based on publicly available sources and industry reports.
